{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Abbott Laboratories
Is Abbott Laboratories overvalued or undervalued?
As of November 21, 2025, Abbott Laboratories is rated as attractive, with a P/E ratio of 19, an EV to EBITDA of 25.84, and a PEG ratio of 0.14, indicating fair valuation and strong growth potential compared to peers like Thermo Fisher and Stryker, despite a one-year return of 9.25% trailing the S&P 500's 11.00%, while outperforming it year-to-date with a return of 13.26% versus 12.26%.
Abbott Laboratories Experiences Revision in Stock Evaluation Amid Market Dynamics
Abbott Laboratories has recently revised its evaluation amid changing market conditions. The stock is priced at $131.38, reflecting a year of notable highs and lows. Technical indicators present mixed signals, while Abbott's year-to-date performance has outpaced the S&P 500, though longer-term returns remain less competitive.
Is Abbott Laboratories technically bullish or bearish?
As of October 10, 2025, Abbott Laboratories shows a mildly bullish trend, supported by a bullish monthly MACD and KST, despite a mildly bearish weekly MACD and mixed performance indicators, having outperformed the S&P 500 recently but lagged over longer periods.
Is Abbott Laboratories technically bullish or bearish?
As of September 12, 2025, Abbott Laboratories is in a bullish trend with strong indicators, outperforming the S&P 500 recently but lagging in long-term returns.
Is Abbott Laboratories overvalued or undervalued?
As of July 17, 2025, Abbott Laboratories is fairly valued with a P/E ratio of 19 and strong growth potential, outperforming peers like Thermo Fisher but lagging in long-term returns compared to the S&P 500.
Abbott Laboratories Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators
Abbott Laboratories has recently revised its evaluation amid changing market conditions. The stock is priced at $131.33, with a year-to-date return of 16.11%, outperforming the S&P 500. However, its longer-term performance over three and five years lags behind the broader market, indicating mixed results.
Is Abbott Laboratories technically bullish or bearish?
As of June 17, 2025, Abbott Laboratories has a mildly bullish trend, supported by bullish monthly indicators and daily moving averages, though tempered by mixed signals from weekly indicators.
Is Abbott Laboratories overvalued or undervalued?
As of June 18, 2025, Abbott Laboratories is considered a very attractive investment due to its undervalued P/E ratio of 19, impressive PEG ratio of 0.14, strong ROE of 27.70%, and favorable comparisons to peers, along with a year-to-date return of 17.81% that significantly outperforms the S&P 500.
Who are in the management team of Abbott Laboratories?
As of March 2022, Abbott Laboratories' management team includes Executive Chairman Miles White, CEO Robert Ford, Lead Independent Director William Osborn, and Independent Directors Robert Alpern, Roxanne Austin, Sally Blount, and Michelle Kumbier. They are responsible for guiding the company's strategic direction and operations.
What does Abbott Laboratories do?
Abbott Laboratories is a large-cap company that develops and sells a wide range of healthcare products in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $10.36 billion and a net profit of $1.3 billion, with a market cap of approximately $258.56 billion.
How big is Abbott Laboratories?
As of Jun 18, Abbott Laboratories has a market capitalization of $258.56 billion, with recent net sales of $42.34 billion and a net profit of $13.43 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
